Such metabolic shifts, influenced by genetic mutations in key oncogenes and tumor suppressor genes, including IDH1, TP53, EGFR, PIK3CA, and NF1 [5], significantly contribute to ITH by fostering an environment conducive to tumor progression and resistance to therapy [6]. This evidence concerns the gene IDH1 and neoplasm.